Bilateral Ovarian Malignant Brenner Tumor: A Case Report with Literature Review
S. Amouzoune1*, A. Belbachir1, S. Berrada1, C. Ahouissoussi1, Y. Khimari2, K. Harou2, A. Soumani2, H. Rais1
1Department
of Anatomy Pathology, Mohammed VI University Hospital, Marrakech, Morocco
2Department of Gynecology, Mohammed VI University Hospital, Marrakech, Morocco
*Corresponding author: S. Amouzoune, Department of Anatomy Pathology, Mohammed VI University Hospital, Marrakech, Morocco Email: salma8amz@gmail.com
Received Date: 03 December,
2018; Accepted Date: 03 January,
2018; Published Date: 09 January,
2019
Citation: Amouzoune S,
Belbachir A, Berrada S, Ahouissoussi C, Khimari Y, et al. (2019) Bilateral
Ovarian Malignant Brenner Tumor: A Case Report with Literature Review. Ann med
clin Oncol 2: 106. DOI: 10.29011/AMCO-106.000106
1.
Abstract
Brenner
tumor of the ovary is very rare, mostly benign, small, and unilateral.
Malignant Brenner Tumor (MBT) is much rarer. We present a patient aged 50
years, with no specific pathological history who presented in consultation for
chronic pelvic pain. Pelvic ultrasound demonstrated a bilateral latero-uterine
mass of suspicious appearance with local infiltration with peritoneal
carcinosis and an ascites of average abundance. The pathological examination
had concluded in a bilateral brenner tumor, endometrium, omentum are all
invaded. Brenner tumors are rare ovarian tumors, first described by
McNaughton-Jones in 1898 and then named by Frits Brenner in 1907. MBT presents
similarly to other ovarian cancers (abdominal distension, abdominal pain, bulk
symptoms and relative vague symptomatology). All histopathological diagnoses
were performed according to the criteria described by Hull and Campbell. Tumors
express several immunohistochemical markers of urothelial differentiation
including uroplakin III, thrombomodulin, GATA3, p63, as well as cytokeratin 7.
The primary treatment modality is surgical excision. This study discussed the
clinical, pathological characteristics and treatment of MBTs.
1.
Introduction
Ovarian Brenner
tumors are relatively rare, comprising 1% to 3% of all ovarian neoplasms [1].
Brenner tumor of the ovary is a relatively uncommon neoplasm. The average age
at presentation is 50 years with 71% of the patients being more than 40 years
[2]. It has a predilection for the postmenopausal woman. According to WHO,
depending on the histopathological pattern, they are classified as benign,
borderline or malignant Brenner tumors, and transitional cell carcinomas [3].
Although Brenner tumors are usually discovered incidentally, patients
occasionally present with symptoms such as a palpable mass or pain [4]. They
are usually unilateral; bilateral lesions are found in 5-14% of cases [4].
Brenner tumor is a fibroepithelial tumor composed of transitional epithelial
cell nests, similar to bladder epithelium [5]. The conventional treatment
modality is surgical resection; however, only a little information is available
on the definition, biology, optimal treatment, and prognosis of Malignant
Brenner Tumors (MBTs) [6].
2.
Case Report
Patient aged 50
years, with no specific pathological history, nulligeste, presented in
consultation for chronic pelvic pain, pelvic ultrasound had objectified a
suspected bilateral ovarian tumor of 5cm / 5cm on each side, with thickened
wall and endokytic vegetations with ascites, vascularized with doppler,
abdomino-pelvic CT demonstrated a bilateral latero-uterine mass of suspicious
appearance with local infiltration with peritoneal carcinosis and an ascites of
average abundance. An exploratory laparotomy made, which had found an
unilateral white-cystic tumor of greyish white appearance, irregular wall
adherent to the neighboring structures, infiltrating the right broad ligaments,
rectum and douglas sac with nodules at the omentum And peritoneal carcinosis, a
total hysterectomy without adnexal preservation with cytological sampling and
an omentectomy with multiple parietal biopsies were performed. The pathological
examination had concluded in a bilateral malignant brenner tumor, endometrium,
omentum are all invaded (Figure 1). The Immunohistochemistry staining results
were positive for: WT-1, cytokeratin 7 and negative for cytokeratin20, and p63
(Figure 2).
3.
Discussion
Ovarian
neoplasms are a heterogeneous group composed of tumors showing epithelial, germ
cell, and sex cord stromal differentiation. The ovarian Brenner Tumor (BT)
represents a rare epithelial ovarian neoplasm and accounts for 1-2% of all
ovarian neoplasms [7] They are rare ovarian tumors, first described by
McNaughton-Jones in 1898 and then named by Frits Brenner in 1907 [6]. In 2013,
Kuhn, et al. suggested a fallopian tube origin for Brenner tumors based on morphologically
identical cilia on the fallopian tube and ovarian surface, as well as a very
similar immunohistochemistry profile in the two tissues [8]. Brenner tumors are
usually benign tumors, although there is a wide spectrum between benign and
malignant features [4]. MBT presents similarly to other ovarian cancers
(abdominal distension, abdominal pain, bulk symptoms and relative vague
symptomatology) [9]. Patients typically present with disease confined to the
ovary or surrounding tissue with lymphatic spread being less common [10].
A
recent retrospective analysis showed that the median tumor size for MBT was 10
cm (10); however, tumor sizes vary with some sources suggesting these neoplasms
are typically much smaller (< 2 cm) (10). Usually, benign Brenner tumors are
unilateral and malignant Brenner tumors are bilateral [4]. Diagnosing Brenner
tumors with imaging studies is difficult because the tumor’s appearance is
nonspecific [4]. In general, it has been shown on CT imaging to have
nonspecific findings, most consistently reported as a mild-moderate enhancement
with evidence of amorphous calcification confined to the solid component [11].
Malignant Brenner tumors are not associated with findings consistent with
hemorrhage or necrosis; however, these features, along with a thick irregular
wall, thick septa and papillary projections are typical features of malignant epithelial
ovarian tumors [7].
All
histopathological diagnoses were performed according to the criteria described
by Hull and Campbell [12], which complemented Idelson's [13] criteria as
follows: (a) presence of malignant histological features; (b) presence of an
intimate association between malignant and benign components or a borderline
Brenner tumor (in the absence of a benign or borderline Brenner component, the
tumor should be classified as a transitional cell
Carcinoma;
(c) absence of mucinous cystadenomas or separation of the mucinous cystadenomas
from both the benign tumor and the MBT; and (d) demonstration of stromal
invasion by epithelial elements of the MBT [6]. The brenner tumor cells have
hyperchromatic, pleomorphic nuclei and numerous mitotic figures, and they are
characterized by destructive stromal invasion [4]. Furthermore, associated
tumor types (most commonly mucinous cystadenoma) must either be absent or
geographically distinct from the MBT [12]. Immunohistochemical stains were
performed to rule out other tumors. CA125, CK7 and WT-1 are positif [7]. The
primary tumor on the differential diagnosis of MBT is Transitional cell carcinoma.
Despite their shared transitional cell phenotype, there is considerable
evidence that these two tumors represent distinct pathologic and clinical
entities. On imaging and gross examination, TCC lacks the calcifications
typically seen in MBT [7]. The TCC is characterized by the presence of nuclei
with distinct nuclear grooves (so-called “coffee-bean” shapes) and can be aided
with immunohistochemical demonstration of urothelial marker expression (such as
GATA3, uroplakin III, thrombomodulin, and p63) [14]. There is one report on the
retroperitoneal metastatic spread of MBT, which was initially limited to the
unilateral ovary without regional or distant metastasis [6]. Thus, a biopsy of
pelvic lymph nodes should be recommended, even if the tumor is localized only
to the unilateral ovary without metastasis. Unilateral oophorectomy is the
procedure of choice only for benign Brenner tumors in patients who desire
ovarian conservation [6]. Ben Aissia, et al. reported that metastasis occurs in
half of the cases and are mostly locoregional [15].
The
treatment for Brenner tumor is essentially surgical. Surgical staging should be
done if a tumor has malignant potential. The role of lymphadenectomy is not yet
clear because of the rare occurence of malignant Brenner tumors. It is reported
that the rate of lymph node metastasis was 5.1% and lymphadenectomy was not
associated with any improvement in survival [10], and Han, et al. [6] reported
that the majority of malignant Brenner tumors presented with localized disease (stage
I). Depending on surgical staging, adjuvant or neoadjuvant chemotherapy is
indicated, however, most authors report low histologic good completion rates,
excluding multi-chemotherapy based on platinum salts [16]. Combining
paclitaxel-carboplatin would be highly recommended [9]. The prognosis depends
on the stages of FIGO, so in stages I survival is estimated at 88% at 5 years.
However, malignant Brenner tumors of advanced stages are poor prognosis with an
average survival at 5 years not exceeding 40% [17]. The factors of poor
prognosis associates, Young age, advanced stage and tumor residue, it should be
noted that in 80% of the cases discovered are good prognosis seen the early
diagnosis in stage I.
4.
Conclusion
The
malignant Brenner tumor is an extremely rare diagnosis of fortuitous discovery,
the prognosis of which remains reserved given the late detection. In the
absence of a therapeutic standard, management is essentially surgical. The
indication of chemotherapy remains questionable and rests on a poly adjuvant
chemotherapy, several protocols remain uncommitted due to the very low
incidence of this malignant form, unlike the benign forms of which the
therapeutic arsenal is well codified and the prognosis generally remains very
Good.
Figure 1: (A): Benign Brenner tumor shows solid and cystic nests of
bland epithelial cells that resemble a transitional epithelium surrounded by
abundant dense fibroblastic stromal tissue. (Hex10; (B): Malignant Brenner tumor component
shows a cytologically malignant component with stromal invasion (He x 40).
Figure 2: Immunohistochemical
stains were performed to rule out other tumors. Wt1 (A) CK7 (B) are positive.
CK20 (C) is negative. Controls were reactive. The results of the stain support
the diagnosis of primary ovarian tumor consistent histologically with malignant
Brenner tumor.
5. Vranes HS, Klaric P, Benkovik
LB, Pirkic A (2005) Brenner tumor of the ovary. Acta Clin Croat 44: 271-273.
12. Hull MG, Campbell GR (1973) The malignant Brenner tumor. Obstet Gynecol
42: 527e34.